Verifying the Specificity of a New Method in Predicting Lymph Node Metastasis in Early Gastric Cancer Patients

Sponsor
Zhaode Bu, MD (Other)
Overall Status
Unknown status
CT.gov ID
NCT03632746
Collaborator
(none)
80
1
28
2.9

Study Details

Study Description

Brief Summary

Early gastric cancer is defined as gastric cancer that only invades mucosal or submucosal layer. The 5-year survival rate of gastric cancer can exceed 90% due to appropriate treatment. The most important consideration is whether there is lymph node metastasis. Preoperative examination including gastroscopy, endoscopic ultrasonography (EUS) and CT are not accurate enough to predict lymph node metastasis in early gastric cancer. In a retrospective study, we created a nomogram to predict lymph node metastasis in early gastric cancer. In prospective validation, the sensitivity and specificity of the nomogram was 75% and 91%, respectively. Sentinel lymph node is a promising concept in early gastric cancer. Using carbon nanoparticles as tracer, the sensitivity and specificity of sentinel lymph node predicting lymph node metastasis in early gastric cancer were 90% and 100%. Based on these results, we proposed a new method that combines the Nomogram and sentinel lymph node to predict lymph node metastasis in early gastric cancer. First, the probability of lymph node metastasis of early gastric cancer patients is calculated by the Nomogram. Those with low incidence of lymph node metastasis continue to the sentinel lymph node procedure. A patient will be considered non lymph node metastasis if his/her frozen pathology of the sentinel lymph nodes is negative during the surgery. Then the standard radical gastrectomy is performed with lymphadenectomy. By comparing postoperative pathology and sentinel lymph node frozen pathology, the specificity of Nomogram combining sentinel lymph node predicting lymph node metastasis in early gastric patients is calculated. The primary endpoint of this research is that the specificity of the above-mentioned method is over 95%.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    80 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Verifying the Specificity of the Method Combining Nomogram and Sentinel Lymph Node in Predicting Lymph Node Metastasis in Early Gastric Cancer Patients: a Prospective, Single Arm, Observational Study
    Anticipated Study Start Date :
    Sep 1, 2018
    Anticipated Primary Completion Date :
    Dec 31, 2020
    Anticipated Study Completion Date :
    Dec 31, 2020

    Outcome Measures

    Primary Outcome Measures

    1. The specificity of the Nomogram combining sentinel lymph node in predicting lymph node metastasis in early gastric cancer patients [10 days after surgery when postoperative pathology result comes out]

    Secondary Outcome Measures

    1. The sensitivity of the Nomogram combining sentinel lymph node in predicting lymph node metastasis in early gastric cancer patients [10 days after surgery when postoperative pathology result comes out]

    2. The sensitivity of the Nomogram alone in predicting lymph node metastasis in early gastric cancer patients [10 days after surgery when postoperative pathology result comes out]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • diagnosed as gastric cancer by gastroscopy

    • pathologically confirmed as adenocarcinoma

    • ages between 18 and 80

    • gastroscopy, abdominal enhanced CT and EUS completed

    • clinical stage T1N0M0

    • the score of the Nomogram less than 110

    • potential resectable gastric cancer

    • signed informed consent

    Exclusion Criteria:
    • absolute indication for endoscopic submucosal dissection (ESD)

    • tumor located in esophagogastric junction (EGJ)

    • accepted adjuvant therap

    • pregnant or breast feeding

    • history of upper abdominal surgery (laparoscopic cholecystectomy not included)

    • history of gastric surgery

    • emergency surgery such as perforation or obstruction

    • other contraindication such as dysfunction of heart, lung, kidney

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Beijing Cancer Hospital Beijing Beijing China 100000

    Sponsors and Collaborators

    • Zhaode Bu, MD

    Investigators

    • Principal Investigator: Zhaode Bu, M.D., Peking University Cancer Hospital & Institute

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Zhaode Bu, MD, Principal Investigator, Peking University Cancer Hospital & Institute
    ClinicalTrials.gov Identifier:
    NCT03632746
    Other Study ID Numbers:
    • Pre gastric preserving study
    First Posted:
    Aug 15, 2018
    Last Update Posted:
    Aug 15, 2018
    Last Verified:
    Aug 1, 2018
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 15, 2018